NCT05172063View on ClinicalTrials.gov

Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness

UnknownOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2023

Conditions
Children With CancerSARS-CoV-2 Infection
Trial Locations (1)

Unknown

Children's Cancer Hospital Egypt 57357 Cairo, Egypt, Cairo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

National Research Centre, Egypt

OTHER

collaborator

Pfizer

INDUSTRY

lead

Children's Cancer Hospital Egypt 57357

OTHER

NCT05172063 - Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness | Biotech Hunter | Biotech Hunter